
    
      MTD will be determined by DLT occurrence and frequency, and severity and charactoristic of
      adverse event, vital sign, physical examination, ECG, Laboratory test, chest-X-ray will be
      examined for safety evaluation.

      The second purpose is to evaluate pharmacokinetics and pharmacodynamics, and immunogenecity
      will be evaluated to investigate antibody production.
    
  